2009 There are 1800 foreign funded pharmaceutical enterprises
in China. The top 20 pharmaceutical companies
set up joint ventures or wholly owned facilities in China. This suggests
that market conditions have never been more challenging, with
competition at an all-time
Pfizer produces and markets more than
40 drugs in China all of which meet chinese pharmacopeia quality control.
manufacturing facilities in Dalian, Suzhou and Wuxi. Pfizer's Dalian
facility, built in 1989 jointly with Dalian Pharmaceuticals was the
first to get certification in China.
GlaxoSmithKline has more than 2000
employees in China, and its drugs are sold in 60 cities. GlaxoSmithKline
mainly sells drugs treating HIV, asthma and
antibiotics prostate drugs,
drugs, pain relievers, osteoporosis and
vaccines. Merck set up its
first joint venture in China in 1994.
four manufacturing facilities in Beijing and Shanghai. Novartis
core businesses involve patented drugs,
generic drugs, eye protection drugs and
health products. Novartis Beijing was founded by Novartis AG and
Beijing Pharmaceutical group and Beijing Zizhu Pharmaceuticals in
1987 and was the first foreign pharmaceutical company in China.
the German-French company, sells several drugs in China.
has headquarters in Shanghai, with 25 branch offices in major cities. In 2001
established its largest manufacturing site in Asia in Wuxi. AstraZeneca sells several products,
including the atypical
antipsychotic used in the management of
schizophrenia and bipolar
disorder Seroquel(quetiapine) and Nexium(esomeprazole). AstraZeneca has nearly 3,000 employees
working in manufacturing, sales, clinical research and new product development.
AstraZeneca has a presence in
more than 110 targeted cities, with around 800 marketing representatives (drug
Bristol-Myers Squibb was one of the
earliest to enter Chinese market.
Johnson & Johnson has
established subsidiaries which include Shanghai Johnson & Johnson
Pharmaceuticals, Ltd, Johnson & Johnson Medical (Shanghai) Ltd,
Johnson & Johnson Medical (China) Ltd, Johnson & Johnson
(China) Ltd, Johnson & Johnson (China) Investment Co., Ltd,
manufacturing and selling drugs in China.
Wyeth's best-seller in
China includes Calcium-D.
Roche launched a medical
education campaign targeting 3,500 doctors in 20 Chinese cities in
Schering-Plough is the recognized leader
in biotechnology, genomics and gene therapy. Shanghai Schering-Plough
Pharmaceutical Co., Ltd was founded in 1994 as a joint-venture, with
Shanghai Pharmaceutical Industry (Group) Corporation and Shanghai
Corporation of Pharmaceutical Economic and Technical International
Bayer's invested in the early 1990s in large-scale,
world-class facilities in an integrated production site in the Shanghai
Chemical Industry Park. Bayer's operations, in Hong Kong, Taiwan, and China
are led by management holding companies, with subgroups and production joint
ventures operating independently under Bayer's strategic direction.
Bayer has production
facilities on stream in all corporately active business lines. Chinese
production accounts for an increasing proportion of profit margins.
Bayer is engaged in a number of
cooperation projects with some of the foremost research institutes and
universities in China, to conduct research in the field of innovative
materials, health care and crop science. Bayer cooperates with the Chinese
Academy of Science and affiliated institutes such as the Institute of
Materia Medica and the Kunming Institute of Botany in Yunnan with
the aim to identify new compounds in the healthcare and crop science field.
There are also a number of projects currently being started in polymers
Bayer supports a number of chairs
and programes for research and teaching at Chinese universities. These include
the Tsinghua-Bayer Public Health and HIV/AIDS Media Studies
Program, a national platform designed to play a key role in China's public
health system. Bayer HealthCare supports a chair for Healthcare
Management at the China European International Business School (CEIBS) in
Boehringer Ingelheim entered Chinese market in
1995 and invested $25 million in a new facility in Shanghai in 2002. Its drugs
diseases and cardiovascular diseases are
established in Chinese pharmaceutical markets.
russell established its China head offices in Beijing in 1995 to manage
operations in mainland China and Hong Kong. Hoechst Marion russell has
two joint ventures in China, Hoechst Huabei Pharmaceuticals Ltd in
Shijiazhuang, a heartland of the Chinese pharmaceutical industry, and
Hoechst Shanghai International Pharmaceuticals Ltd.
Eli Lilly set up
its first overseas office in Shanghai in 1918 and returned to Shanghai, China
in 1993. Eli
Lilly main facility is in Suzhou, Jiangsu province and main products
include cipro, insulin, and erectile dysfunction drugs.
Laboratories Ltd sells a series of products including baby food in
Among foreign-invested ventures in China, Xian-Janssen
Pharmaceutical's success is due to its product line, which includes a range
of high-volume sellers: medicines to treat gastronintestinal problems, fungi,
allergies and pain, as well as
epilepsy. Dr. Paul Janssen's
decision to enter China early, to invest
inland, and to keep investment plans moving along in the wake of 1989 Tiananmen
Square event have helped build good relations with the Chinese government. Paul
Appermont and Joos Horsten lead the Xian-Janssen Pharmaceutical project.
Degussa is shifting a large proportion of its pharmaceutical
chemicals production from Europe to China in order to take advantage of
low-cost manufacturing. Degussa will restructure its large production
facilities, the vast majority in Germany, which could result in the transfer of
the manufacture of other products to China.
Rhodia is improving
its competitive position in analgesics by making a major investment in its
Wuxi, China acetaminophen (paracetamol) production facility and consolidating
its North American and European operations. Rhodia shuttered its Luling,
Louisiana, acetaminophen (paracetamol) operations in 2004 and consolidated
production in Roussillon, France and Wuxi, China. Acetaminophen (paracetamol)
production capacity will be adjusted to match current consumption levels.
Sankyo has operated a plant for manufacturing the hyperlipemic
Mevalotin(pravastatin), anti-inflammatory Loxonin(loxoprofen),
antibiotic Banan(cephalosporin antibiotic) and has plans to market
hypertensive Olmesartan(angiotensin II receptor antagonists).
Takeda has a manufacturing plant and will be marketing all four
global products - the thiazolidinedione with hypoglycemic action
Actos(pioglitazone), anti-ulcer proton pump
inhibitorTakepron(lansoprazole), gonadotropin-releasing hormone agonist
cancer drug Leuplin(leuprolide acetate), and hypertensive
Yamanouchi owns a manufacturing
plant and is marketing anti-ulcer histamine H2-receptor antagonist
Gaster(famotidine), urinary impediment treatment
Harnal(tamsulosin), a selective alpha blocker used in the symptomatic
treatment of benign prostatic hyperplasia and hypertensive calcium channel
blocker Hypoca. There are plans to launch Dolner for peripheral
circulation and anti-emetic Nazea OD.
sells synthetic antibacterials Cravit (oral and injectable levofloxacin)
and Tarivid(ofloxacin). It originally planned to launch
neurotransmission enhancer Translon too, but after development was
halted in Japan, development in China also ended. Sales are behind plan chiefly
due to the suspension of Translon's development and the proliferation of
generic and copycat versions of
Tanabe markets hypertensive
Herbesser(diltiazem hydrochloride) and Tanatril (imidapril
The China subsidiary Kuangchou Green Cross of
Mitsubishi Pharma has been extending transfusion business
(manufacturing, sales) since the days of the former Green Cross.
Mitsubishi Pharma sold its transfusion business in Japan to Otsuka
Pharmaceutical as part of a restructuring. Anti-coagulant
Novastan(argatroban) was launched in China in December 2002 and is being
sold by a local agent.
Immunosuppressant Prograf(tacrolimus or
fujimycin) is being marketed in China by a Fujisawa subsidiary -
potential is significant due to the ever increasing number of organ
transplants. In 2000, there were 5,501 kidney transplants performed in China,
second only to the number in the US (13,372). Sales of immunosuppressant drugs
are relatively high. The top 30 drugs by sales in China (hospital market base)
included two such drugs: Novartis' immunosuppressant drug used in
post-allogeneic organ transplantNeoral(cyclosporine) and Roche's
immunosuppressant drug used to prevent rejection in organ transplantation
CellCept (mycophenolate mofetil).
Chugai exports white
blood cell production stimulant Neutrogin (lenograstim) to China.
Kirin's granulocyte colony-stimulating factor is marketed in
Eisai expanded its manufacturing and marketing operations
in China and Asia earlier than in the European and US markets. Eisai was
the first manufacturer among the US, European and Japanese pharmaceutical firms
to manufacture in China via a 100% owned subsidiary which founded in 1994.
Eisai sells two global products, anti-ulcer proton pump inhibitors
Pariet(rabeprazole) and Alzheimer's acetylcholinesterase inhibitor
treatment Aricept(donepezil), and plans to add
Glakay(menatetrenone) in 2006.
Kyowa Hakko has exported
cancer drugs and plans to market the hypertensive dihydropyridine calcium
channel blockerConiel(benidipine) and anti-allergy antihistamine and
mast cell stabilizer Allelock(olopatadine
Taisho makes and sells health drinks (tonics) in
China, but has no specific plans for prescription medications. The rights to
macrolide antibiotic Clarith/Biaxin(clarithromycin) outside Japan
are licensed to Abbott.
Terumo is using China as a
manufacturing base making products for the US and European and Japanese
markets. Terumo is in the process of exploring China as a
The first foreign office of the FDA opened November
19, 2008 in Beijing.
recall 2009 McNeil Consumer Healthcare, a division of Johnson &
Johnson, announced the recall of several hundred batches of popular
over-the-counter medicines, including Benadryl, Motrin, Rolaids, Simply Sleep,
St. Joseph Aspirin and Tylenol. The response was anything but swift. The recall
came 20 months after McNeil first began receiving consumer complaints about
moldy-smelling bottles of Tylenol Arthritis Relief caplets. Johnson &
Johnson did not conduct a timely, comprehensive investigation, did not quickly
identify the source of the problem, and did not notify authorities in a timely
fashion thus prolonging consumer exposure to the products.
This web site is not a commercial web site and
is presented for educational purposes only.
This website defines a
new perspective with which to engage reality to which its author adheres. The
author feels that the falsification of reality outside personal experience has
created a populace unable to discern propaganda from reality and that this has
been done purposefully by an international corporate cartel through their
agents who wish to foist a corrupt version of reality on the human race.
occurs when any group refuses to tolerate religious practices, religious
beliefs or persons due to their religious ideology. This web site marks the
founding of a system of philosophy named The Truth of the Way of Life - a
rational religion based on reason which requires no leap of faith, accepts no
tithes, has no supreme leader, no church buildings and in which each and every
individual is encouraged to develop a personal relation with the Creator and
Sustainer through the pursuit of the knowledge of reality in the hope of curing
the spiritual corruption that has enveloped the human spirit. The tenets of The
Truth of the Way of Life are spelled out in detail on this web site by the
author. Violent acts against individuals due to their religious beliefs in
America is considered a "hate crime."
This web site in no way condones
violence. To the contrary the intent here is to reduce the violence that is
already occurring due to the international corporate cartels desire to control
the human race. The international corporate cartel already controls the world
economic system, corporate media worldwide, the global industrial military
entertainment complex and is responsible for the collapse of morals, the
elevation of self-centered behavior and the destruction of global ecosystems.
Civilization is based on cooperation. Cooperation does not occur at the point
of a gun.
American social mores and values have declined precipitously
over the last century as the corrupt international cartel has garnered more and
more power. This power rests in the ability to deceive the populace in general
through corporate media by pressing emotional buttons which have been
preprogrammed into the population through prior mass media psychological
operations. The results have been the destruction of the family and the
destruction of social structures that do not adhere to the corrupt
international elites vision of a perfect
world. Through distraction and coercion the direction of thought of the
bulk of the population has been directed toward solutions proposed by the
corrupt international elite that further consolidates their power and which
further their purposes.
All views and opinions presented on this web
site are the views and opinions of individual human men and women that, through
their writings, showed the capacity for intelligent, reasonable, rational,
insightful and unpopular thought. All factual information presented on this web
site is believed to be true and accurate and is presented as originally
presented in print media which may or may not have originally presented the
facts truthfully. Opinion and thoughts have been adapted, edited, corrected,
redacted, combined, added to, re-edited and re-corrected as nearly all opinion
and thought has been throughout time but has been done so in the spirit of the
original writer with the intent of making his or her thoughts and opinions
clearer and relevant to the reader in the present time.
Fair Use Notice
This site may contain copyrighted material the use of which has
not always been specifically authorized by the copyright owner. We are making
such material available in our efforts to advance understanding of criminal
justice, human rights, political, economic, democratic, scientific, and social
justice issues, etc. We believe this constitutes a 'fair use' of any such
copyrighted material as provided for in section 107 of the US Copyright Law. In
accordance with Title 17 U.S.C. Section 107, the material on this site is
distributed without profit to
those who have expressed a prior interest in receiving the included information
for research and educational purposes. For more information see:
www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted
material from this site for purposes of your own that go beyond 'fair use', you
must obtain permission from the copyright owner.
© Lawrence Turner
All Rights Reserved